Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.25%
#3 Glidr Glidr +36.87%
#4 CoW Protocol CoW Protocol +33.48%
#5 Humanity Humanity +26.28%
#6 RedStone RedStone +22.97%
#7 Codatta Codatta +22.46%
#8 Walrus Walrus +17.94%
#9 Enso Enso +17.47%
#10 The Black Bull The Black Bull +15.54%
Coin of the day
EXOD EXOD
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Affimed N.V. Affimed N.V.

Affimed N.V.

AFMD
Classificação em ações #36349
Affimed N.V. operates as a clinical-stage biopharmaceutical enterprise,... Affimed N.V. operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts on the identification and advancement of innovative cancer immunotherapies across the United States, Germany, and the broader European region. A key asset in their development pipeline is AFM13. This candidate has successfully concluded its Phase II clinical study for peripheral T-cell lymphoma and is currently progressing through Phase IIa trials for CD30-positive lymphoma, alongside a Phase I trial for Hodgkin lymphoma. Beyond AFM13, Affimed is actively developing several other therapeutic candidates. These include AFM24, a distinctive tetravalent, bispecific innate cell engager designed to target both epidermal growth factor receptor (EGFR) and CD16A; it is presently undergoing Phase IIa clinical trials for a range of advanced cancers. Further back in the pipeline are AFM28, an innate cell engager (ICE) in preclinical development for acute myeloid leukemia, and AFM32, another ICE candidate also in preclinical stages, aimed at solid tumors. The company has forged strategic collaboration agreements with prominent institutions such as The University of Texas MD Anderson Cancer Center, Genentech, Inc., and Roivant Sciences Ltd. Moreover, it benefits from a research funding agreement with The Leukemia & Lymphoma Society. Founded in 2000 and headquartered in Heidelberg, Germany, the organization transitioned its name to Affimed N.V. in October 2014, having previously operated as Affimed Therapeutics B.V.
Preço da ação
$0.1815
Última sincronização: 2026-04-06
Valor de mercado
$2.78M
Variação (1 dia)
0.00%
Variação (1 ano)
365.38%
País
DE
Negociar Affimed N.V. (AFMD)

Categoria

Healthcare
Margem Operacional de Affimed N.V. (AFMD)
Margem Operacional em 2026 TTM: 0.00%
De acordo com os relatórios financeiros mais recentes e o preço das ações da Affimed N.V., a margem operacional atual (TTM) é 0.00%. No final de 2026, a margem operacional era 0.00%.
Histórico da Margem Operacional da Affimed N.V. de 2026 a 2026
Margem Operacional no final de cada ano
Ano Margem Operacional Alterar
Não há dados suficientes para as datas fornecidas.
Margem Operacional de empresas semelhantes ou concorrentes
Empresa Margem Operacional Diferença na Margem Operacional País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.